62 related articles for article (PubMed ID: 17657223)
1. Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma.
Dold SM; Riebl V; Wider D; Follo M; Pantic M; Ihorst G; Duyster J; Zeiser R; Wäsch R; Engelhardt M
Haematologica; 2020 Oct; 105(10):e523. PubMed ID: 33054097
[No Abstract] [Full Text] [Related]
2. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
Noori S; Wijnands C; Langerhorst P; Bonifay V; Stingl C; Touzeau C; Corre J; Perrot A; Moreau P; Caillon H; Luider TM; Dejoie T; Jacobs JFM; van Duijn MM
Blood Cancer J; 2023 Feb; 13(1):30. PubMed ID: 36828828
[No Abstract] [Full Text] [Related]
3. Functional and psychological impact of minimal residual disease assessment on patients with multiple myeloma.
Correia N; Dowling E; Popat R; Rabin N; Kyriakou C; Sive J; Yong K; Wechalekar A
Br J Haematol; 2023 Sep; 202(5):e43-e45. PubMed ID: 37353905
[No Abstract] [Full Text] [Related]
4. Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure!
Landgren O; Kazandjian D
J Clin Oncol; 2022 Sep; 40(25):2863-2866. PubMed ID: 35772041
[No Abstract] [Full Text] [Related]
5. The next frontier of early lung cancer and minimal residual disease detection: is multiomics the solution?
Rolfo C; Russo A; Malapelle U
EBioMedicine; 2023 Jun; 92():104605. PubMed ID: 37156171
[No Abstract] [Full Text] [Related]
6. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Bladé J; Mateos MV; Dimopoulos M; Kastritis E; Boccadoro M; Orlowski R; Goldschmidt H; Spencer A; Hou J; Chng WJ; Usmani SZ; Zamagni E; Shimizu K; Jagannath S; Johnsen HE; Terpos E; Reiman A; Kyle RA; Sonneveld P; Richardson PG; McCarthy P; Ludwig H; Chen W; Cavo M; Harousseau JL; Lentzsch S; Hillengass J; Palumbo A; Orfao A; Rajkumar SV; Miguel JS; Avet-Loiseau H
Lancet Oncol; 2016 Aug; 17(8):e328-e346. PubMed ID: 27511158
[TBL] [Abstract][Full Text] [Related]
7. Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients.
Pojero F; Casuccio A; Di Bassiano F; Gervasi F; Colonna Romano G; Caruso C
Immun Ageing; 2015; 12():5. PubMed ID: 26101540
[TBL] [Abstract][Full Text] [Related]
8. oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival.
Fujisawa M; Seike K; Fukumoto K; Suehara Y; Fukaya M; Sugihara H; Takeuchi M; Matsue K
Cancer Sci; 2014 Nov; 105(11):1442-6. PubMed ID: 25182124
[TBL] [Abstract][Full Text] [Related]
9. Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.
Tete SM; Bijl M; Sahota SS; Bos NA
Front Immunol; 2014; 5():257. PubMed ID: 24917865
[TBL] [Abstract][Full Text] [Related]
10. Profiling human antibody responses by integrated single-cell analysis.
Ogunniyi AO; Thomas BA; Politano TJ; Varadarajan N; Landais E; Poignard P; Walker BD; Kwon DS; Love JC
Vaccine; 2014 May; 32(24):2866-73. PubMed ID: 24602776
[TBL] [Abstract][Full Text] [Related]
11. A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma.
Robillard N; Béné MC; Moreau P; Wuillème S
Blood Cancer J; 2013 Aug; 3(8):e134. PubMed ID: 23955589
[No Abstract] [Full Text] [Related]
12. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma.
Lobetti-Bodoni C; Mantoan B; Monitillo L; Genuardi E; Drandi D; Barbero D; Bernocco E; Boccadoro M; Ladetto M
Ther Adv Hematol; 2013 Jun; 4(3):189-98. PubMed ID: 23730496
[TBL] [Abstract][Full Text] [Related]
13. An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.
Nakayama S; Yokote T; Hirata Y; Iwaki K; Akioka T; Miyoshi T; Takayama A; Nishiwaki U; Masuda Y; Ikemoto T; Tanaka H; Nishimura Y; Tsuji M; Hanafusa T
Diagn Pathol; 2012 Sep; 7():131. PubMed ID: 23021410
[TBL] [Abstract][Full Text] [Related]
14. Assessing minimal residual disease in chronic lymphocytic leukemia.
Rawstron AC; Hillmen P
Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
[TBL] [Abstract][Full Text] [Related]
15. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease.
Domingo E; Moreno C; Sánchez-Ibarrola A; Panizo C; Páramo JA; Merino J
Haematologica; 2010 Apr; 95(4):691-2. PubMed ID: 19951967
[No Abstract] [Full Text] [Related]
16. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
[No Abstract] [Full Text] [Related]
17. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice.
Owen RG; Rawstron AC
Br J Haematol; 2005 Mar; 128(5):732-3; author reply 733-4. PubMed ID: 15725097
[No Abstract] [Full Text] [Related]
18. An analysis of the false negative rate of minimal residual disease measurement by multiparameter flow cytometry in multiple myeloma.
Austin M; O'Connor S; Morilla R; Pawlyn C; Kaiser MF; Boyd KD
Int J Lab Hematol; 2020 Apr; 42(2):e65-e67. PubMed ID: 31539199
[No Abstract] [Full Text] [Related]
19. Monitoring of minimal residual disease in multiple myeloma after allo-SCT: flow cytometry vs PCR-based techniques.
Lioznov M; Badbaran A; Fehse B; Bacher U; Zander AR; Kröger NM
Bone Marrow Transplant; 2008 May; 41(10):913-6. PubMed ID: 18264143
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
